France Selected Germany's Boerhinger Ingelheim Over Zoetis For Bird Flu Vaccines
Portfolio Pulse from Charles Gross
France has chosen Germany's Boehringer Ingelheim over Zoetis for bird flu vaccines, according to Reuters. This decision could potentially impact the stock performance of both companies.
July 12, 2023 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
France's decision to choose Boehringer Ingelheim for bird flu vaccines could potentially impact the iShares MSCI France ETF (EWQ).
While the decision could have some impact on the French market, it's difficult to predict the exact effect on the EWQ ETF without more specific information about the size and terms of the deal.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Zoetis was not selected by France for bird flu vaccines, which could negatively impact its stock in the short term.
Zoetis was in contention for the bird flu vaccine contract with France but was not selected. This could lead to a short-term negative impact on its stock as it represents a lost opportunity for revenue and growth.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80